Development of Miltefosine for the Leishmaniases

descriptionPublicationkeyboard_double_arrow_right Article 01 Feb 2006 English Publisher:Bentham Science Publishers Ltd.Journal:Mini-Reviews in Medicinal Chemistry, volume 6, pages 145-151 (issn: 1389-5575,

Copyright policy )

Authors: J D, Berman;

doi: 10.2174/138955706775475993

pmid: 16472183

Development of Miltefosine for the Leishmaniases

- Summary
- Subjects
- Metrics

Abstract

The leishmaniases consist of visceral and cutaneous syndromes present in > 30 endemic regions of the world. Miltefosine (hexadecylephosphocholine) is the first oral agent that is effective and tolerated for both visceral and cutaneous disease in several endemic regions, and represents a major advance in the treatment of these diseases.

Related Organizations

National Institute of Health
Pakistan
National Center for Complementary and Integrative Health
United States
National Institutes of Health
United States

Keywords

Adult, Clinical Trials as Topic, Drug Design, Phosphorylcholine, Antiprotozoal Agents, Humans, HIV Infections, Child, Leishmaniasis

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	30
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%